Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)

K. Kakkar, Ajay; N. Levine, Mark; Kadziola, Zbigniew; R. Lemoine, Nicholas; Warren Low, V.; K. Patel, Heman; Rustin, Gordon; J. Thomas, Michael; Quigley, Mary; C N Williamson, R

doi:10.1200/jco.2004.10.002

Public

Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)

Published in Journal of Clinical Oncology • May 13, 2004

Authors:

Ajay K. Kakkar

Mark N. Levine

Zbigniew Kadziola

Abstract

PURPOSE: In experimental systems, interference with coagulation can affect tumor biology. Furthermore, it has been suggested that low molecular weight heparin therapy may prolong survival in patients with cancer. The primary aim of this study was to assess survival at 1 year of patients with advance...

Subject

Medicine

Placebo

Randomization

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!